

S 637

CURE High Drug Prices Act

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 28, 2019

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 28, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/637>

Sponsor

Name: Sen. Blumenthal, Richard [D-CT]

Party: Democratic • **State:** CT • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Harris, Kamala D. [D-CA]	D · CA		Feb 28, 2019
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 28, 2019
Sen. Merkley, Jeff [D-OR]	D · OR		Feb 28, 2019
Sen. Sanders, Bernard [I-VT]	I · VT		Feb 28, 2019
Sen. Schatz, Brian [D-HI]	D · HI		Feb 28, 2019

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 28, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 4158	Related bill	Aug 5, 2019: Referred to the Subcommittee on Health.

Summary (as of Feb 28, 2019)

Combatting Unreasonable Rises and Excessively High Drug Prices Act or the CURE High Drug Prices Act

This bill prohibits price gouging by manufacturers of prescription drugs (including a combination of a drug, device, or biological product) that are covered by a federal health care program. The bill specifies percentage increases in price at which price gouging is presumed.

Actions Timeline

- **Feb 28, 2019:** Introduced in Senate
- **Feb 28, 2019:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.